Pacific Biosciences Of California (PACB) Short term Debt (2010 - 2023)

Pacific Biosciences Of California's Short term Debt history runs 6 years deep, the most recent figure standing at $96.2 million for Q3 2023.

• On a quarterly basis, Short term Debt changed N/A year-over-year to $96.2 million in Q3 2023; TTM through Sep 2023 was $96.2 million, a N/A change from a year earlier, with the FY2022 full-year figure at $172.1 million, up 10602.36% from the prior year.
• Short term Debt fell to $96.2 million in Q3 2023 per PACB's latest filing, from $186.3 million in the prior quarter.
• Across five years, Short term Debt topped out at $186.3 million in Q2 2023 and bottomed at $1.6 million in Q4 2021.
• The 3-year median for Short term Debt is $172.1 million (2022), against an average of $128.1 million.
• Biggest YoY gain for Short term Debt was 10602.36% in 2022; the steepest drop was 10602.36% in 2022.
• Year by year, Short term Debt stood at $1.6 million in 2021, then jumped by 10602.36% to $172.1 million in 2022, then slumped by 44.1% to $96.2 million in 2023.
• Per Business Quant, the three latest PACB Short term Debt figures stand at $96.2 million (Q3 2023), $186.3 million (Q2 2023), and $184.4 million (Q1 2023).